Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms

Oncogene

Volumn 22, Issue 5, 2003, Pages 660-664

  Zermati, Yael ^a   De Sepulveda, Paulo ^b   Féger, Frederic ^a   Létard, Sebastion ^b   Kersual, Joelle ^a   Castéran, Nathalie ^b   Gorochov, Guy ^c   Dy, Michel ^a   Dumas, Antoni Ribadeau ^a   Dorgham, Karim ^c   Parizot, Christophe ^c   Bieche, Yann ^e   Vidaud, Michel ^e   Lortholary, Olivier ^f   Arock, Michel ^a   Hermine, Olivier ^a,d   Dubreuil, Patrice ^b,g  

^a CNRS   (France)

^b INSERM   (France)

^c Laboratoire d'Immunologie Cellulaire et Tissulaire CNRS URA 625   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f AVICENNE HOSPITAL   (France)

^g INSTITUT PAOLI CALMETTES   (France)

Author keywords

C kit; Kinase inhibitor; Mastocytosis; STI571

Indexed keywords

IMATINIB; PHOSPHOTRANSFERASE; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR RECEPTOR;

ANIMAL CELL; ARTICLE; CELL SURVIVAL; CLINICAL ARTICLE; CODON; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DESIGN; DRUG EFFECT; DRUG SELECTIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; GENE MUTATION; HUMAN; HUMAN CELL; MAST CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SYSTEMIC MASTOCYTOSIS;

ANTINEOPLASTIC AGENTS; CATALYTIC DOMAIN; CELL LINE; ENZYME INHIBITORS; HUMANS; MASTOCYTOSIS, SYSTEMIC; PIPERAZINES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; STRUCTURE-ACTIVITY RELATIONSHIP;

ANIMALIA;

EID: 0344987886     PISSN: 09509232     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.onc.1206120     Document Type: Article

References (25)

1. Beghini A, Peterlongo P, Ripamonti CB, Larizza L, Cairoli R, Morra E and Mecucci C. (2000). Blood, 95, 726-727.
2. Beslu N, LaRose J, Casteran N, Birnbaum D, Lecocq E, Dubreuil P and Rottapel R. (1996). J. Biol. Chem., 271, 20075-20081.
3. Buchdunger E, Cioffi CL, Law N, Stor FD, Ohno-Jones S, Druker BJ and Lyndon ND. (2000). J. Pharmacol. Exp. Ther., 295, 139-145.
4. Butterfield JH, Weiler D, Dewald G and Gleich GJ. (1988). Leuk. Res., 12, 345-355.
5. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S and Sawyers CL. (2001). N. Engl. J. Med., 344, 1031-1037.
6. Hermine O, Mayeux P, Titeux M, Mitjavila MT, Casadevall N, Guichard J, Komatsu N, Suda T, Miura Y and Vainchenker W. (1992). Blood, 80, 3060-3069.
7. Hongyo T, Li T, Syaifudin M, Baskar R, Ikeda H, Kanakura Y, Aozasa K and Nomura T. (2000). Cancer Res., 60, 2345-2347.
8. Horny HP and Valent P. (2001). Leuk. Res., 25, 543-551.
9. Issaad C, Ahmed M, Novault S, Bonnet ML, Bennardo T, Varet B, Vainchenker W and Turhan AG. (2000). Leukemia, 14, 662-670.
10. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman S, Capdeville R, Dimitrijevic S, Druker B and Demetri GD. (2001). N Engl. J. Med., 344, 1052-1056.
11. Kitamura Y, Go S and Hatanaka K. (1978). Blood, 52, 447-452.
12. Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA, Walker H, Wheatley K, Bowen DT, Burnett AK, Goldstone AH and Linch DC. (2001). Blood, 98, 1752-1759.
13. Longley BJ and Metcalfe DD. (2000). Hematol. Oncol. Clin. North Am., 14, 697-701.
14. Longley BJ, Metcalf DD, Thrap M, Wang X, Tyrrell L, Lu S-Z, Heitzan D, and Tha Y. (1999). Proc. Natl. Acad. Sci. USA, 96, 1609-1614.
15. Longley J, Duffy TP and Kohn S. (1995). J. Am. Acad. Dermatol., 32, 545-561.
16. Marone G, Spadaro G, Granata F and Triggiani M. (2001). Leuk. Res., 25, 583-594.
17. Tsujimura T, Hashimoto K, Kitayama H, Ikeda H, Sugahara H, Matsumura I, Kaisho T, Terada N, Kitamura Y and Kanakura Y. (1999). Blood, 93, 1319-1329.
18. Tsujimura T, Morimoto M, Hashimoto K, Moriyama Y, Kitayama H, Matsuzawa Y, Kitamura Y and Kanakura Y. (1996a). Blood, 87, 273-283.
19. Tsujimura T, Moriyama Y, Yamatodani A, Kimura M, Tohya K, Morimoto M, Kitayama H, Kanakura Y and Kitamura Y. (1996b). Am. J. Pathol, 148, 189-200.
20. Tuveson DA, Willis NA, Jacks T, Griffin JD, Singer S, Fletcher CD, Fletcher JA and Demetri GD. (2001). Oncogene, 20, 5054-5058.
21. Valent P, Horny HP, Escribano L, Longley BJ, Li CY, Schwartz LB, Marone G, Nunez R, Akin C, Sotlar K, Sperr WR, Wolff K, Brunning RD, Parwaresch RM, Austen KF, Lennert K, Metcalfe DD, Vardiman JW and Bennett JM. (2001). Leuk. Res., 25, 603-625.
22. Valent P, Spanblochl E, Sperr WR, Sillaber C, Zsebo KM, Agis H, Strobl H, Geissler K, Bettelheim P and Lechner K. (1992). Blood, 80, 2237-2245.
23. Worobec AS. (2000). Hematol. Oncol. Clin. North Am., 14, 659-687.
24. Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S, Asou N, Kuriyama K, Yagasaki F, Shimazaki C, Akiyama H, Saito K, Nishimura M, Motoji T, Shinagawa K, Takeshita A, Saito H, Ueda R, Ohno R and Naoe T. (2001). Blood, 97, 2434-2439.
25. Zermati Y, Varet B and Hermine O. (2000). Exp. Hematol., 28, 256-266.